Literature DB >> 2796381

Acute lymphoblastic leukemia of NK-cell lineage: responses to IL-2.

S J Pirruccello1, M S Bicak, B G Gordon, K Gajl-Peczalska, D J Gnarra, P F Coccia.   

Abstract

Acute lymphoblastic leukemias with phenotypic characteristics of natural killer cell derived lineage are extremely uncommon. We identified an ALL with a phenotype consistent with an NK-cell of origin. The blasts underwent a proliferative response to r-IL2 in culture but showed no spontaneous or r-IL2 or gamma-INF induced cytotoxicity. With r-IL2 stimulation however, the tumor cells demonstrated a dramatic acquisition of low density CD8 surface positivity and a loss of CD11b expression after short term culture. By comparison to ALL of B or T lineage, NK ALL likely represents an early stage of bone marrow derived NK-cell precursor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2796381     DOI: 10.1016/0145-2126(89)90086-6

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Hemagglutination and graft-versus-host disease in the severe combined immunodeficiency mouse lymphoproliferative disease model.

Authors:  S J Pirruccello; H Nakamine; K W Beisel; K L Kleveland; M Okano; Y Taguchi; J R Davis; M L Mahloch; D T Purtilo
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

2.  Two entities of precursor T-cell lymphoblastic leukemia/lymphoma based on radiologic and immunophenotypic findings.

Authors:  Yasushi Onishi; Yoshihiro Matsuno; Ukihide Tateishi; Akiko Miyagi Maeshima; Masahiko Kusumoto; Takashi Terauchi; Shigeru Kusumoto; Naohiro Sekiguchi; Kazuki Tanimoto; Takashi Watanabe; Yukio Kobayashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

Review 3.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

4.  Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas.

Authors:  Lubomir Sokol; Thomas P Loughran
Journal:  Curr Treat Options Oncol       Date:  2003-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.